| Ident. | Authors (with country if any) | Title |
|---|
| 000503 |
Davide Chiasserini [Italie] ; Alessandro Tozzi [Italie] ; Antonio De Lure [Italie] ; Michela Tantucci [Italie] ; Federica Susta [Italie] ; Pier Luigi Orvietani [Italie] ; Keizo Koya [États-Unis] ; Luciano Binaglia [Italie] ; Paolo Calabresi [Italie] | Mortalin Inhibition in Experimental Parkinson's Disease |
| 001451 |
Penelope J. Hallett [États-Unis] ; J. M. Brotchie [Canada] | Striatal delta opioid receptor binding in experimental models of Parkinson's disease and dyskinesia |
| 002472 |
Lance A. Smith [Royaume-Uni] ; Michael J. Jackson ; Matthew J. Hansard ; Eleni Maratos ; Peter Jenner | Effect of pulsatile administration of Levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: Effect of dose, frequency of administration, and brain exposure |
| 002582 |
Ronald K. B. Pearce [Royaume-Uni] ; Lance A. Smith [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Tara Banerji [Royaume-Uni] ; Jorgen Scheel-Krüger [Danemark] ; Peter Jenner [Royaume-Uni] | The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosets |
| 002626 |
Lance A. Smith [Royaume-Uni] ; Banu C. Tel [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Matthew J. Hansard [Royaume-Uni] ; Rogelio Braceras [Royaume-Uni] ; Céline Bonhomme [France] ; Claire Chezaubernard [France] ; Susanna Del Signore [France] ; Sarah Rose [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | Repeated administration of Piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: A behavioural and biochemical investigation |
| 002911 |
Oum-Kaltoum Hassani [France] ; Mireille Mouroux [France] ; Georg Andrees Bohme [France] ; Jean-Marie Stutzmann [France] ; Jean Feger [France] | Riluzole reduces hyperactivity of subthalamic neurons induced by unilateral 6-OHDA lesion in the rat brain |
| 002969 |
L. Munro-Davies [Royaume-Uni] ; J. Winter [Royaume-Uni] ; T. Z. Aziz [Royaume-Uni] ; J. Stein [Royaume-Uni] | Kainate acid lesions of the pedunculopontine region in the normal behaving primate |
| 002C12 |
R. G. Geocadin [États-Unis] ; J. Muthuswamy [États-Unis] ; D. L. Sherman [États-Unis] ; N. V. Thakor [États-Unis] ; D. F. Hanley [États-Unis] | Early electrophysiological and histologic changes after global Cerebral ischemia in rats |
| 002C25 |
S. Palfi [États-Unis] ; L. Leventhal [États-Unis] ; C. G. Goetz [États-Unis] ; P. Hantraye [France] ; B.-Z. Roitberg [États-Unis] ; J. Sramek [États-Unis] ; M. Emborg [États-Unis] ; J. H. Kordower [États-Unis] | Delayed onset of progressive dystonia following subacute 3-nitropropionic acid treatment in Cebus apella monkeys |
| 002D01 |
B. Henry [Royaume-Uni] ; S. H. Fox [Royaume-Uni] ; D. Peggs [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] ; J. M. Brotchie [Royaume-Uni] | The α2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-Parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease |
| 003128 |
L. Rioux [États-Unis] ; P. A. Frohna [États-Unis] ; J. N. Joyce [États-Unis] ; J. S. Schneider [États-Unis] | The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys |
| 003379 |
P. J. Blanchet [Canada] ; R. Grondin ; P. J. Bedard | Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates |
| 003564 |
R. J. Vermeulen [Pays-Bas] ; B. Drukarch [Pays-Bas] ; M. C. R. Sahadat ; C. Goosen ; E. C. Wolters [Pays-Bas] ; J. C. Stoof [Pays-Bas] | The dopamine D1 agonist SKF 81297 and the dopamine D2 agonist LY 171555 act synergistically to stimulate motor behavior of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian rhesus monkeys |
| 003592 |
D. D. Truong [États-Unis] ; R. R. Matsumoto [États-Unis] ; P. H. Schwartz [États-Unis] ; M. J. Hussong [États-Unis] ; C. G. Wasterlain | Novel rat cardiac arrest model of posthypoxic myoclonus |
| 003595 |
J. D. Belluzzi [États-Unis] ; E. F. Domino ; J. M. May ; K. S. Bankiewicz ; D. A. Mcafee | N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease |
| 003610 |
G. E. Borodic [États-Unis] ; R. Ferrante ; L. Bruce Pearce ; K. Smith [États-Unis] | Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injections |
| 003671 |
I. Rektor [France] ; M. Svejdova ; C. Silva-Barrat ; C. Menini | The cholinergic system-dependent myoclonus of the baboon Papio papio is a reticular reflex myoclonus |
| 003676 |
S. B. Blunt [Royaume-Uni] ; P. Jenner [Royaume-Uni] ; C. D. Marsden | Suppressive effect of L-dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine |
| 003685 |
C. A. Hubbard [États-Unis] ; J. M. Trugman | Reversal of reserpine-induced catalepsy by selective D1 and D2 dopamine agonists |
| 003708 |
K. T. Finnegan [États-Unis] | Neurotoxins and monoamine oxidase inhibition: new aspects |
| 003733 |
B. Gomez-Mancilla [Canada] ; R. Boucher ; C. Gagnon ; T. Di Paolo ; R. Markstein ; P. J. Bedard | Effect of adding the D1 agonist CY 208-243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors |
| 003777 |
J. D. Wirtschafter [États-Unis] ; D. P. Slovut ; L. Stordal ; J. Valentino ; L. K. Mcloon | Severe but temporary injury to rabbit orbicularis oculi muscle using dihematoporphyrin ether and laser photochemomyectomy |
| 003779 |
I. J. Mitchell [Royaume-Uni] ; A. R. Crossman ; U. Liminga ; P. Andren ; L. M. Gunne | Regional changes in 2-deoxyglucose uptake associated with neuroleptic-induced tardive dyskinesia in the cebus monkey |
| 003819 |
B. Gomez-Mancilla [Canada] ; J.-F. Latulippe ; R. Boucher ; P. J. Bedard | Effect of ethosuximide on rest tremor in the MPTP monkey model |
| 003821 |
B. Gomez-Mancilla [Canada] ; R. Boucher ; P. J. Bedard | Effect of LY 171555 and CY 208-243 on tremor suppression in the MPTP monkey model of Parkinsonism |
| 003864 |
R. Kurlan [États-Unis] ; M. H. Kim ; D. M. Gash | Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys : assessment with a new rating scale for monkey parkinsonism |
| 003867 |
S. Brailowsky | Myoclonus in Papio papio |
| 003870 |
T. Z. Aziz [Royaume-Uni] ; D. Peggs ; M. A. Sambrook ; A. R. Crossman | Lesion of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonims in the primate |
| 003875 |
G. Pezzoli [Italie] ; A. Zecchinelli ; S. Ricciardi ; R. E. Burke ; S. Fahn ; G. Scarlato ; A. Carenzi | Intraventricular infusion of epidermal growth factor restores dopaminergic pathway in hemiparkinsonian rats |
| 003903 |
J. M. Brotchie ; I. J. Mitchell ; M. A. Sambrook ; A. R. Crossman | Alleviation of Parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate |
| 003922 |
N. M. J. Rupniak ; S. J. Tye ; M. J. Steventon ; S. Boyce ; S. D. Iversen | Spontaneous orofacial dyskinesias in a captive cynomolgus monkey : implications for tardive dyskinesia |
| 003935 |
U. Wahnschaffe ; G. Fredow ; P. Heintz ; W. Loêscher | Neuropathological studies in a mutant hamster model of paroxysmal dystonia |
| 003937 |
I. J. Mitchell ; R. Luquin ; S. Boyce ; C. E. Clarke ; R. G. Robertson ; M. A. Sambrook ; A. R. Crossman | Neural mechanisms of dystonia: evidence from a 2-deoxyglucose uptake study in a primate model of dopamine agonist-induced dystonia |
| 003943 |
S. Boyce ; C. E. Clarke ; R. Luquin ; D. Peggs ; R. G. Robertson ; I. J. Mitchell ; M. A. Sambrook ; A. R. Crossman | Induction of chorea and dystonia in parkinsonian primates |
| 003985 |
W. R. G. Gibb ; M. Terruli ; Andrew Lees (neurologue) [Royaume-Uni] ; P. Jenner ; C. D. Marsden | The evolution and distribution of morphological changes in the nervous system of the common marmoset following the acute administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine |
| 003A18 |
J. A. Temlett ; N. P. Quinn ; P. G. Jenner ; C. D. Marsden ; E. Pourcher ; A.-M. Bonnet ; Y. Acid ; R. Markstein ; X. Lataste | Antiparkinsonian activity of CY 208-243, a partial D-1 dopamine receptor agonist, in MPTP-treated marmosets and patients with Parkinson's disease |
| 003A33 |
A. B. Scott ; D. Suzuki | Systemic toxicity of botulinum toxin by intramuscular injection in the monkey |
| 003A47 |
D. Dung Truong ; J. Garcia De Yebenes ; G. Pezzoli ; V. Jackson-Lewis ; S. Fahn | Glycine involvement in DDT-induced myoclonus |
| 003A74 |
W. Koller ; G. Herbster ; J. Gordon | PHNO, a novel dopamine agonist, in animal models of parkinsonism |
| 003A90 |
J. G. De Yebenes ; S. Fahn ; S. Lovelle ; V. Jackson-Lewis ; P. Jorge ; M. A. Mena ; J. Reiriz ; J. C. Bustos ; C. Magarinos ; A. Martinez | Continuous intracerebroventricular infusion of dopamine and dopamine agonists through a totally implanted drug delivery system in animal models of Parkinson's disease |
